Vyas KP - Search Results

1

The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.

Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, Baillie TA. Halpin RA, et al. Among authors: vyas kp. Drug Metab Dispos. 2002 Jun;30(6):684-93. doi: 10.1124/dmd.30.6.684. Drug Metab Dispos. 2002. PMID: 12019196

2

Metabolism of rofecoxib in vitro using human liver subcellular fractions.

Slaughter D, Takenaga N, Lu P, Assang C, Walsh DJ, Arison BH, Cui D, Halpin RA, Geer LA, Vyas KP, Baillie TA. Slaughter D, et al. Among authors: vyas kp. Drug Metab Dispos. 2003 Nov;31(11):1398-408. doi: 10.1124/dmd.31.11.1398. Drug Metab Dispos. 2003. PMID: 14570773

3

In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.

Prueksaritanont T, Gorham LM, Breslin MJ, Hutchinson JH, Hartman GD, Vyas KP, Baillie TA. Prueksaritanont T, et al. Among authors: vyas kp. Drug Metab Dispos. 1997 Aug;25(8):978-84. Drug Metab Dispos. 1997. PMID: 9280406

4

Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.

Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez-Eng C, Matuszewski BK, Varga SL, Guiblin AR, Rogers JD. Vyas KP, et al. Drug Metab Dispos. 2000 Jan;28(1):89-95. Drug Metab Dispos. 2000. PMID: 10611145

5

Metabolism of A dopamine D(4)-selective antagonist in rat, monkey, and humans: formation of A novel mercapturic acid adduct.

Zhang KE, Kari PH, Davis MR, Doss G, Baillie TA, Vyas KP. Zhang KE, et al. Among authors: vyas kp. Drug Metab Dispos. 2000 Jun;28(6):633-42. Drug Metab Dispos. 2000. PMID: 10820134

6

The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.

Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP. Halpin RA, et al. Among authors: vyas kp. Drug Metab Dispos. 2000 Oct;28(10):1244-54. Drug Metab Dispos. 2000. PMID: 10997947

7

Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.

Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T, Melillo D, Vyas KP. Baillie TA, et al. Among authors: vyas kp. Drug Metab Dispos. 2001 Dec;29(12):1614-28. Drug Metab Dispos. 2001. PMID: 11717181

8

Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.

Vyas KP, Kari PH, Pitzenberger SM, Halpin RA, Ramjit HG, Arison B, Murphy JS, Hoffman WF, Schwartz MS, Ulm EH, et al. Vyas KP, et al. Drug Metab Dispos. 1990 Mar-Apr;18(2):203-11. Drug Metab Dispos. 1990. PMID: 1971574

9

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE. Halpin RA, et al. Among authors: vyas kp. Drug Metab Dispos. 1993 Nov-Dec;21(6):1003-11. Drug Metab Dispos. 1993. PMID: 7905377

10

In vitro and in vivo studies on the metabolism of tirofiban.

Vickers S, Theoharides AD, Arison B, Balani SK, Cui D, Duncan CA, Ellis JD, Gorham LM, Polsky SL, Prueksaritanont T, Ramjit HG, Slaughter DE, Vyas KP. Vickers S, et al. Among authors: vyas kp. Drug Metab Dispos. 1999 Nov;27(11):1360-6. Drug Metab Dispos. 1999. PMID: 10534322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters